OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 90.2-91
◽
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 355.3-356
◽
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 742.2-743
◽
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 133-134
◽
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 608.1-608
2017 ◽
Vol 76
(6)
◽
pp. AB47
2017 ◽
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 346.1-346
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 341.1-341